Retavacyl 625 is a combination antibiotic tablet containing 625 mg of co-amoxiclav, comprising 500 mg of amoxicillin and 125 mg of clavulanic acid. This combination enhances the efficacy of amoxicillin against bacterial infections by inhibiting beta-lactamase enzymes produced by certain bacteria.

Indications:

Retavacyl 625 is prescribed for treating various bacterial infections, including:

• Respiratory tract infections (e.g., pneumonia, bronchitis)

• Ear infections (otitis media)

• Sinus infections (sinusitis)

• Urinary tract infections

• Skin and soft tissue infections

• Bone and joint infections

• Dental infections

Dosage and Administration:

• Adults: One tablet every 8 hours, taken with food to reduce the risk of stomach upset.

• Duration: Typically prescribed for 7 to 10 days, depending on the severity of the infection.

Important Considerations:

• Contraindications: Retavacyl 625 should not be used by individuals allergic to penicillins, clavulanic acid, or any component of the formulation.

• Drug Interactions: Inform your healthcare provider about all medications you are taking, as Retavacyl 625 may interact with other drugs, including anticoagulants and other antibiotics.

• Side Effects: Common side effects may include nausea, vomiting, diarrhea, and skin rashes. Seek medical attention if severe allergic reactions occur, such as difficulty breathing or swelling of the face and throat.

Storage:

Store Retavacyl 625 tablets in a cool, dry place, away from direct sunlight, and out of reach of children.

Always consult with a healthcare professional before starting any new medication to ensure it is appropriate for your specific health needs.